ASCO/ESMO 2020 - KEYNOTE 048 Study Update, What Have We Learned?

Here's a new head and neck cancer video.  Not only can't I say enough about how much I appreciate learning about new findings but they speak about the fact that they have different approaches to the same case description.  Just knowing that lets me know I need to discuss my goals and options for treatment when there isn't a clear direction. 

"For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss what we have learned from Keynote 048: First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC"I

I hope this helps someone or many someones

Janine